4//SEC Filing
Rubin Michael P. 4
Accession 0000950170-24-014000
CIK 0001994702other
Filed
Feb 11, 7:00 PM ET
Accepted
Feb 12, 5:51 PM ET
Size
13.7 KB
Accession
0000950170-24-014000
Insider Transaction Report
Form 4
Transactions
- Conversion
Common Stock
2024-02-12+2,805,426→ 2,805,426 total(indirect: By: Northpond Ventures III, LP) - Purchase
Common Stock
2024-02-12$22.00/sh+450,000$9,900,000→ 450,000 total(indirect: By: Northpond Ventures, LP) - Conversion
Series B Preferred Stock
2024-02-12−12,767,776→ 0 total(indirect: By: Northpond Ventures III, LP)→ Common Stock (2,805,426 underlying)
Transactions
- Conversion
Common Stock
2024-02-12+2,805,426→ 2,805,426 total(indirect: By: Northpond Ventures III, LP) - Conversion
Series B Preferred Stock
2024-02-12−12,767,776→ 0 total(indirect: By: Northpond Ventures III, LP)→ Common Stock (2,805,426 underlying) - Purchase
Common Stock
2024-02-12$22.00/sh+450,000$9,900,000→ 450,000 total(indirect: By: Northpond Ventures, LP)
Rubin Michael P.
Other
Transactions
- Conversion
Common Stock
2024-02-12+2,805,426→ 2,805,426 total(indirect: By: Northpond Ventures III, LP) - Purchase
Common Stock
2024-02-12$22.00/sh+450,000$9,900,000→ 450,000 total(indirect: By: Northpond Ventures, LP) - Conversion
Series B Preferred Stock
2024-02-12−12,767,776→ 0 total(indirect: By: Northpond Ventures III, LP)→ Common Stock (2,805,426 underlying)
Footnotes (3)
- [F1]Immediately prior to the closing of the initial public offering of Kyverna Therapeutics, Inc. (the "Issuer"), each share of Series B Convertible Preferred Stock, par value $0.00001 per share (the "Series B Preferred Stock"), of the Issuer automatically converted on a 4.5511-for-1 basis into shares of the Issuer's common stock, par value $0.00001 per share (the "Common Stock"). The Series B Preferred Stock had no expiration date.
- [F2]Northpond Ventures III GP, LLC ("Northpond III LLC") is the general partner of Northpond Ventures III, LP ("Northpond Fund III"), and Michael P. Rubin is the managing member of Northpond III LLC. As a result, each of Northpond III LLC and Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund III. Each of Northpond III LLC and Mr. Rubin disclaim beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any.
- [F3]Northpond Ventures GP, LLC ("Northpond LLC") is the general partner of Northpond Ventures, LP ("Northpond Fund"), and Michael P. Rubin is the managing member of Northpond LLC. As a result, Mr. Rubin may be deemed to share beneficial ownership with respect to the shares held of record by Northpond Fund. Mr. Rubin disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest therein, if any.
Documents
Issuer
Kyverna Therapeutics, Inc.
CIK 0001994702
Entity typeother
Related Parties
1- filerCIK 0001867627
Filing Metadata
- Form type
- 4
- Filed
- Feb 11, 7:00 PM ET
- Accepted
- Feb 12, 5:51 PM ET
- Size
- 13.7 KB